Perinatal OUD Continuity & Retention
Deep Dive Materials
About This Enrichment Document: This companion provides extended references, fellow-ready case vignettes, care model comparisons, policy considerations, and emerging research on perinatal OUD continuity and retention through 12 months postpartum.
Extended References & Evidence Base
Methadone and buprenorphine discontinuation among postpartum women with OUD
n=2,314; 64.1% continued MOUD for full 12 months. Earlier initiation predicted retention: 80% for full pregnancy vs 34% for final month initiators.
2. Cross-Sectional Analysis: MOUD Treatment Episodes (2015-2021)
n=29,981 treatment episodes. MOUD inclusion increased from 65.0% to 74.1%. Medicaid expansion states: 72% MOUD inclusion vs 48% in non-expansion states.
3. VCU Integrated OB/Addiction Clinic Study (2023)
n=127; low-threshold, harm reduction model achieved 69% buprenorphine continuation at 6 months. 95% had psychiatric comorbidities; 79.5% utilized mental health services.
Fellow-Ready Case Vignettes
Vignette 1: Early Engagement & Integrated Care
28-year-old G2P1 at 14 weeks, referred from ED after positive urine opioid screen. Reports daily fentanyl use × 2 years. History of anxiety, PTSD from childhood abuse. Medicaid insured. Stable housing with partner who also uses.
Questions for Discussion:
- What is first-line treatment? → MOUD with buprenorphine or methadone; avoid withdrawal (59-90% relapse)
- ASAM dimension analysis: D1 (daily fentanyl, withdrawal risk), D3 (PTSD/anxiety), D5 (high relapse risk with partner use), D6 (partner actively using)
- How do you address partner's substance use within Plan of Safe Care?
Key Teaching Points: Partner substance use is a major predictor of postpartum relapse. Safety planning must address the home environment. Peer recovery specialists can help engage both partners.
Vignette 2: Postpartum Handoff Failure
30-year-old, 3 days postpartum, on methadone 80 mg via OTP. Infant in NICU for NOWS monitoring. Told Medicaid will end at 60 days postpartum. Social worker documented CPS referral. Expresses intent to leave AMA.
Questions for Discussion:
- How does fear of CPS involvement affect treatment engagement?
- What warm-handoff elements are essential before discharge?
- How would you counsel about Medicaid postpartum extension (now 12 months in most states)?
- What is the overdose risk trajectory over the next 12 months if she disengages?
Key Teaching Points: Fear of CPS is a major barrier—punitively framed policies predict 43% higher odds of no planned MOUD. Medicaid extension addresses the 60-day coverage gap that drives discontinuation.
Vignette 3: Tele-MOUD & Equity
24-year-old Black woman, rural county, G1 at 28 weeks. OUD diagnosed at 20 weeks but no buprenorphine prescriber within 60 miles. Medicaid insured. No reliable transportation.
Questions for Discussion:
- What care delivery model addresses geographic barriers? → Tele-MOUD; now permanently authorized for buprenorphine initiation
- How do racial disparities affect MOUD likelihood? → Black women receive MOUD at ~31% vs 57% for White women
- ASAM D6 assessment: rural isolation, transportation barriers. How does this inform level-of-care recommendation?
Care Model Deep Dive
Co-located OB–Addiction Clinic (Medical Home)
Key Success Factors:
• One-stop care reduces transportation barriers
• "Warm handoffs" occur internally—no referral slips
• Normalization of SUD treatment in obstetrical setting reduces stigma
• Flexible, low-threshold access (no mandated groups)
Tele-MOUD: Evidence and Implementation
| Study | Finding | Implication |
|---|---|---|
| Kentucky (2022) | 48% vs 44% 90-day retention | Tele-MOUD equivalent to in-person |
| OHSU (2024) | 3.8% vs 9.7% 6-month discontinuation | Lower discontinuation with telehealth |
| Scoping Review (2024) | No differences in outcomes | Telehealth appropriate for pregnancy/postpartum |
DEA Update (2023): Telehealth flexibilities made permanent—buprenorphine may be initiated via phone or video, including in OTPs. Critical for rural access.
Policy Environment Analysis
Punitive vs Supportive Policy Effects
| Policy Type | Impact on MOUD Receipt | Impact on Overdose |
|---|---|---|
| Punitive (criminalization) | +43% odds of no planned MOUD | +45% opioid overdoses |
| Supportive (treatment funding) | +11% MOUD receipt | -45% opioid overdoses |
| Medicaid 12-month extension | +8.55% MOUD months | Improved access |
Racial Disparities in Policy Implementation
Research demonstrates that Black women are disproportionately subject to:
- Drug testing in pregnancy (higher rates despite similar use patterns)
- CPS reporting for substance-exposed infants
- Criminal prosecution for substance use in pregnancy
These disparities drive the 37-day delay in OUD diagnosis for minority women and the 0.51 vs 0.65 retention probability gap.
Emerging Research
Predictive Modeling for Retention
Machine learning approaches using EHR data (demographics, SDOH, MOUD timing, comorbidities) show promise for predicting 12-month retention. Early findings suggest:
- Earlier MOUD initiation is the strongest predictor (OR 4.2)
- Housing instability and benzodiazepine use are high-risk markers
- Integrated care setting reduces predicted discontinuation by 40%
Medication Dosing and Retention
Higher buprenorphine doses at delivery predict postpartum continuation. Consider:
- Split dosing in 3rd trimester (metabolic changes)
- Adequate loading doses during induction
- Avoid forced dose reductions postpartum (normalization of metabolism may reduce need)
Peer Recovery Support RCT (Ongoing)
Randomized trial of peer recovery specialists in perinatal settings (n=400). Interim analysis shows:
- +23% MOUD initiation in peer-supported arm
- +18% 6-month retention
- Higher patient satisfaction scores (trust, cultural competency)
Additional Resources
- ASAM Criteria: Application to perinatal populations (training modules available)
- Medicaid Postpartum Extension Tracker (KFF)
- National Drug Court Institute: Family Treatment Court standards
- State Harm Reduction Strategies (AMCHP database)